Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer

被引:17
作者
Gui, GPH
Joubert, DJ
Reichert, R
Ward, A
Lakhani, S
Osin, P
Nerurkar, A
A'Hern, R
Benson, K
Underwood, SR
机构
[1] Royal Marsden NHS Fdn Trust, Acad Surg & Breast Unit, London SW3 6JJ, England
[2] Royal Marsden NHS Fdn Trust, Dept Pathol Anat, London SW3 6JJ, England
[3] Royal Marsden NHS Fdn Trust, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JJ, England
[4] Royal Marsden NHS Fdn Trust, Dept Informat Technol & Stat, London SW3 6JJ, England
[5] Royal Brompton Hosp, Dept Nucl Med, London SW3 6LY, England
来源
EJSO | 2005年 / 31卷 / 07期
关键词
sentinel lymph node biopsy; axillary dissection; axillary sample; sensitivity;
D O I
10.1016/j.ejso.2005.04.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Sentinel lymph node biopsy (SLNB) has become increasingly accepted as a diagnostic method to stage the axilla in breast cancer, selecting women with a positive sentinel node for completion axillary clearance. As SLNB became established, many surgeons supplemented SLNB to sample a minimum of four lymph nodes, on the assumption that the four-node technique is supported by randomised trial data. We hypothesised that the practice of undirected sampling to supplement SLNB adds little information to the status of the residual axilla. Methods: One hundred and sixty-five patients with early breast cancer were studied. Following successful identification of the sentinel node, 84 women had completion axillary dissection and 81 women had an axillary sample with at least four nodes available for pathological assessment. Results: Following successful identification of the sentinel node in 165 patients, the false negative rate (FNR) was 2/44=4.5% (95% Cl 0.6-15.5), sensitivity 42/44=95.5% (84.5-99.4) and negative predictive value (NPV) 121/123 = 98.4% (94.2-99.8). In the axillary dissection cohort, the FNR was 2/26=7.7% (0.9-25.1), sensitivity 24/26= 92.3% (74.9-99.1) and NPV 58/60=96.7% (88.5-100). In the axillary sample group, the FNR was 0/18 = 0% (0-18.5), sensitivity 18/18 = 100% (81.5-100) and NPV 63/63=100% (94.3-100). The SLNB was the only positive node in 12/26 (46.2%) in the axillary dissection group and 10/18 (55.6%) in the axillary sampling group. There was no patient in the axillary sampling group where the sample node was positive and the sentinel node negative. Conclusion: Once SLNB is validated within the multidisciplinary unit, undirected sampling of the axilla following identification of the sentinel node(s) is unnecessary. The additional sampling of non-sentinel nodes has no rote to play either in the assessment of a potential false negative SLNB nor as predictive information on the status of the residual axillary nodes. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:707 / 714
页数:8
相关论文
共 31 条
[1]   Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer [J].
Ahlgren, J ;
Holmberg, L ;
Bergh, J ;
Liljegren, G .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (02) :97-102
[2]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[3]   Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection [J].
Borgstein, P ;
Pijpers, R ;
Comans, EF ;
van Diest, PJ ;
Boom, RP ;
Meijer, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (03) :275-283
[4]  
Cady B, 1996, ARCH SURG-CHICAGO, V131, P301
[5]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[6]  
2-H
[7]   Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial [J].
Chetty, U ;
Jack, W ;
Prescott, RJ ;
Tyler, C ;
Rodger, A .
BRITISH JOURNAL OF SURGERY, 2000, 87 (02) :163-169
[8]   Sentinel node biopsy in breast cancer: ALMANAC trial [J].
Clarke, D ;
Khonji, NI ;
Mansel, RE .
WORLD JOURNAL OF SURGERY, 2001, 25 (06) :819-822
[9]   Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer [J].
Cox, CE ;
Pendas, S ;
Cox, JM ;
Joseph, E ;
Shons, AR ;
Yeatman, T ;
Ku, NN ;
Lyman, GH ;
Berman, C ;
Haddad, F ;
Reintgen, DS .
ANNALS OF SURGERY, 1998, 227 (05) :645-653
[10]  
Cserni G, 1999, Pathol Oncol Res, V5, P129, DOI 10.1053/paor.1999.0174